Method and device for testing plurality of biological samples

By preparing discrete entities containing markers in the imaging container, and identifying and tracking biological samples using optical readouts, multiple biological samples tracking problems in a single container are solved, improving the efficiency and accuracy of single-cell analysis.

CN119001092APending Publication Date: 2024-11-22LEICA MICROSYSTEMS CMS GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410615639.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-17
Filing Date
2024-05-17
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

When processing large numbers of biological samples in a single container, it is difficult to track and identify the characteristics of each individual sample, especially in 3D cell cultures to identify and isolate rare cells such as reactive T cells and circulating tumor cells.

Method used

By preparing multiple discrete entities in an imaging container, each entity containing a polymeric compound, a biological sample and a marker, an optical readout is generated to determine the characteristics of the marker and the biological sample-related characteristics, thereby uniquely identifying and tracking of the target discrete entities.

Benefits of technology

The unique identification and tracking of multiple biological samples in a single container is achieved, supporting further processing and analysis, such as cell culture, bioproduct production and downstream analysis, improving the efficiency and accuracy of single-cell analysis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119001092A_ABST
    Figure CN119001092A_ABST
Patent Text Reader

Abstract

A method of testing a plurality of biological samples comprises the steps of preparing a plurality of discrete entities (100, 1800), each discrete entity (100, 1800) comprising a polymeric compound, at least one biological sample (108), and a marker (110). A plurality of discrete entities (100, 1800) are arranged in an imaging container (102). At least one first optical readout of at least one discrete entity (100, 1800) of the plurality of discrete entities (100, 1800) is generated. From the first optical readout, a first characterization of a marker (110) of at least one discrete entity (100, 1800) of the plurality of discrete entities (100, 1800) and at least one characteristic associated with the biological sample (108) are determined. At least one discrete entity (100, 1800) of the plurality of discrete entities (100, 1800) from the imaging container (102) is identified as a target discrete entity (100, 1800) based on at least one characteristic associated with the biological sample (108) and a first characterization of the marker (110) of the at least one discrete entity (100, 1800).
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a method for testing a plurality of biological samples. The present invention also relates to a device for testing a plurality of biological samples. Background Art

[0002] Rare cells such as adult stem cells, circulating tumor cells, and reactive immune cells (e.g., T cells, B cells, or NK cells that respond to a certain antigen) are of great interest to basic and translational researchers. For example, a B cell clone that can respond to a pathogen (e.g., a virus) and produce antibodies against a specific target molecule of that pathogen is of great value for generating much-needed therapeutic antibodies. Similarly, reactive T cells are also sought in personalized medicine and the treatment of diseases such as cancer. Once reactive T cells are identified and isolated, the gene sequence encoding the corresponding T cell receptor can be cloned to give it affinity for the target antigen and used to generate genetically engineered T cells such as CAR-T cells. Similarly, circulating tumor cells are expected to play an important role in diagnosing cancer, predicting outcomes, managing therapy, and discovering new cancer drugs and cell therapies. Typically, a cell suspension containing rare cells can be extracted from a tissue sample or liquid biopsy by dissociation. Therefore, the identification, analysis and isolation of rare cells in these samples, especially the analysis of these cells at the single cell level (single cell analysis, SCA), is of great value for basic and translational research, diagnostic and therapeutic applications, and the bioprocessing, development and manufacturing of biologics and cell therapies.

[0003] Recent advances in the field of cell culture research have led to the advent of 3D cell culture, which is based on culturing cells in three dimensions, such as suspension culture (scaffold-free technology) or embedded in hydrogels and / or extracellular matrices (scaffold-based technology). Hydrogels and extracellular matrices are widely used in scaffold-based 3D cell culture along with other elements. Cells and other elements can be effectively embedded in discrete entities such as hydrogel microbeads in various ways for suspension culture and imaging. Hydrogel microbeads come in a variety of forms, including single-phase, multiphase, mixed-phase, hollow, and solid hydrogel microbeads with or without shells, and can be manufactured using a variety of methods such as microfluidics, 3D printing, emulsification, or electrospraying.

[0004] This allows large numbers of cells, including rare cells, to be grown in 3D cell culture for analytical, diagnostic and therapeutic purposes.

[0005] Cell culture embedded in hydrogels (i.e., scaffold-based cell culture) maintained in a suspended state combines the advantages of scaffold-based cell culture and suspension cell culture, and is therefore a cell culture mode with broad application prospects. In many processing flows based on such cell culture, it is necessary to be able to repeatedly identify single discrete entities. For example, when processing a large number of single cells (including rare cells) in collective 3D cell culture, it is very important to be able to track individual entities or cells during the experiment. In this way, rare cells can be identified, analyzed, and separated from a large number of cells. However, it is currently not possible to track each entity and cell while processing a large number of entities and cells in a single container. Summary of the invention

[0006] An object of the present invention is to provide a method and apparatus for testing a plurality of biological samples, which enables a user to uniquely identify and track a single identified biological sample based on at least one characteristic associated with the biological sample.

[0007] The above objects can be achieved by the subject matter of the independent claims. The dependent claims and the following description define advantageous embodiments.

[0008] The proposed method for testing a plurality of biological samples comprises the following steps: preparing a plurality of discrete entities, wherein each discrete entity comprises a polymeric compound, at least one biological sample, and a marker. Arranging the plurality of discrete entities in an imaging container. Generating at least one first optical readout of at least one discrete entity in the plurality of discrete entities. Determining a first representation of the marker of at least one discrete entity in the plurality of discrete entities and at least one characteristic associated with the biological sample based on the first optical readout. Identifying at least one discrete entity from the plurality of discrete entities in the imaging container as a target discrete entity based on the at least one characteristic associated with the biological sample and the first representation of the marker of the at least one discrete entity.

[0009] For example, by forming hydrogel beads composed of a marker and at least one biological sample, a plurality of discrete entities can be prepared outside the imaging container. In particular, the biological sample can be any of the above-mentioned biological samples, such as reactive immune cells, reactive T cells or tumor cells. The marker can be an optically detectable pattern, structure and / or distribution characteristics of an optically detectable element. The marker will be described in detail with reference to the embodiments below. In the process of preparing a plurality of discrete entities, more discrete entities that do not contain biological samples and / or markers may be accidentally generated. In this article, these discrete entities are not considered to be part of a plurality of discrete entities. The prepared plurality of discrete entities are transferred or loaded into an imaging container, such as a culture dish, a microscope slide, a microplate or a similar suitable container. Then, a first optical readout is generated from the imaging container containing the plurality of discrete entities. In particular, the optical readout can be an image or a digital image. After obtaining the optical readout, image data is generated based on the first optical readout, and the image data is further processed to determine a first representation of the marker and at least one characteristic associated with the biological sample. Based on the first characterization of the marker and at least one characteristic associated with the biological sample, at least one discrete entity is identified as one of the target discrete entities, so as to be further processed, for example. The further processing may include retrieving the biological sample from the target discrete entity, further culturing and amplification, biological product production, bioprocessing, fermentation, cloning genes and downstream analysis. Downstream analysis may include genome, transcriptome, proteome analysis, transcription factor binding analysis (such as ChIP-Seq, etc.), DNA methylation analysis, metabolome analysis, etc.

[0010] When processing a large number of biological samples, especially when processing a large number of biological samples in a single container such as an imaging container, it is difficult to track a single sample. The discrete entity combines one of the biological samples with a marker. Because the marker is configured to be unique to the biological sample, a user can uniquely identify each biological sample. Therefore, the method enables a user to track the biological samples collected in the imaging container during an experiment. In particular, the method enables a user to uniquely identify and track the identified target discrete entity based on at least one characteristic associated with the biological sample. Therefore, the method can perform time-lapse experiments on single cells, cell populations, co-cultures, spheroids, tumors, or organoids, for example, to perform cell-based tests, including cell viability tests, cell proliferation tests, cytotoxicity tests, cell senescence tests, and cell death tests.

[0011] Alternatively, the proposed method for testing a plurality of biological samples comprises the following steps: preparing a plurality of discrete entity precursors, each precursor comprising a polymeric compound and at least one biological sample coated by the polymeric compound. Arranging the plurality of discrete entity precursors in an imaging container. Creating a plurality of discrete entities from the plurality of discrete entity precursors, each discrete entity comprising a polymeric compound, a biological sample, and a marker. Generating at least one first optical readout of at least one discrete entity in the plurality of discrete entities. Based on the first optical readout, determining a first representation of a marker of at least one discrete entity in the plurality of discrete entities and at least one characteristic associated with the biological sample. Identifying at least one discrete entity from the plurality of discrete entities from the imaging container as a target discrete entity based on at least one characteristic associated with the biological sample and the first representation of the marker of the at least one discrete entity.

[0012] This alternative method differs from the previously described method in that the plurality of discrete entities are prepared in the imaging container using a plurality of discrete entity precursors. Apart from this, the alternative method is the same as the previously described method and has the same advantages. In particular, the relevant features of the previously described method can be used to supplement this alternative method.

[0013] In a preferred embodiment, the biological sample and the marker are coated by a polymeric compound. Alternatively or additionally, the polymeric compound further comprises a marker, and the biological sample is coated by the polymeric compound regardless of whether it is labeled by the marker. When preparing the discrete entity, the polymeric compound can be polymerized to form the discrete entity. The polymerized polymeric compound enables the cultivation of biological samples in discrete entities, such as culturing biological samples in scaffold-based suspended 3D cell culture, thereby combining the advantages of 3D suspension cell culture and scaffold-based cell culture. In particular, it provides a way to take advantage of the key advantages of 3D suspension cell culture, including: improved mixing and aeration through the use of stirring vessels such as rotating bioreactors, rotating bottles, stirring tanks or shaking bioreactors, the possibility of running continuous culture medium exchange, and the possibility of online processing control while growing samples in scaffolds such as hydrogels, extracellular matrices and / or basement membranes, which provides a more physiological environment for the sample in terms of matrix elasticity, chemical composition, attachment points, and paracrine and autocrine signals.

[0014] In a further preferred embodiment, the method comprises the additional step of immobilizing a plurality of discrete entities or a plurality of discrete entity precursors in the imaging container. The discrete entities may be immobilized by attaching the discrete entities to the imaging container, for example by centrifuging the discrete entities to the surface of the imaging container. Immobilizing the plurality of discrete entities can prevent the discrete entities from moving in the imaging container when the imaging container is moved, for example during generation of an optical readout, thereby making it easier to track the target discrete entities.

[0015] By centrifuging the discrete entity to the surface of the imaging container, the discrete entity can be easily distributed roughly evenly in the imaging container. In addition, the discrete entity can also be fixed by attaching the discrete entity to a functionalized surface or embedding it in a second hydrogel or polymer compound. The above embedding can be either placing the discrete entity in the hydrogel or polymer compound before or while the hydrogel or polymer compound is polymerized, or placing the discrete entity first and then covering it with a suitable hydrogel or polymer compound. The hydrogel or polymer compound can be a hydrogel or polymer compound used to prepare discrete entities with different viscosities (i.e., gel concentrations). For example, the discrete entity can be prepared using 0.8% low melting point agarose and then embedded in 0.6% low melting point agarose. Alternatively, the matrix used to prepare the discrete entity can be different from the matrix used to embed the discrete entity. The matrix or polymer compound used to embed the discrete entity may contain functionalized components that can be selectively depolymerized by ultraviolet-induced, temperature-induced, chemical-induced or enzyme-induced cleavage. In this way, the release of the target discrete entity can be controlled.

[0016] In another preferred embodiment, the method includes the additional step of extracting at least one discrete entity from the plurality of discrete entities from the imaging container based on at least one characteristic associated with the biological sample and the first characterization of the marker of the at least one discrete entity. In this embodiment, the at least one target discrete entity can be removed from the imaging container for further processing. For example, the discrete entity can be removed from the imaging container by suction. For example, removing the target discrete entity from the imaging container allows for further study in a specific environment away from the remaining discrete entities.

[0017] According to another preferred embodiment, the method includes the additional step of generating at least one second optical readout after a preset time period. Based on the second optical readout, a second representation of a marker of at least one of the plurality of discrete entities and a property associated with the biological sample are determined. The first representation and the second representation are compared to identify at least one of the plurality of discrete entities. The property associated with the biological sample determined based on the first optical readout is compared with the property associated with the biological sample determined based on the second optical readout. In this embodiment, the method preferably also includes the additional step of extracting at least one of the plurality of discrete entities from the imaging container based on the comparison. In this embodiment, a time series measurement is performed. At a first time point in the time series, a first optical readout is generated and a first value of the property associated with the biological sample is determined. At a second time point in the time series, a second optical readout is generated and a second value of the property associated with the biological sample is determined. The value of the property may have changed between the first optical readout and the second optical readout. For example, the expression amount of a specific protein can be determined based on the second optical readout.

[0018] In another preferred embodiment, the method includes an additional step of culturing the discrete entity between the first optical readout and the second optical readout, in particular culturing a biological sample that is part of the discrete entity. Cultivating the biological sample may include treating it with a compound, a biological compound (e.g., a protein, a signaling molecule, a nucleic acid, an antigen, a neoantigen, an antibody), a pathogen (e.g., a virus, a bacterium, a parasite), a bioactive agent (e.g., CRISPR, RNAi), a mechanical, electrical or photophysical stimulus. Therefore, this embodiment implements a processing flow for comparing the state of the biological sample between at least two time points (i.e., the time points before and after the culturing step). The state of the biological sample before and after the treatment can be determined based on the first optical readout and the second optical readout. In addition, this embodiment can also perform time-lapse experiments, for example, using single cells, cell groups, co-cultures, spheroids, tumor cells or organ tissues as biological samples. Similarly, various cell-based tests commonly used in phenotypic screening can also be performed in this embodiment. Such cell-based tests include cell viability tests, cell proliferation tests, cytotoxicity tests, cell senescence tests and cell death tests. Importantly, cells or cell populations identified as target biological samples in the manner described above can be extracted and / or further processed.

[0019] In another preferred embodiment, the method includes the additional step of arranging a fluid or liquid culture medium in the imaging container before arranging the plurality of discrete entities or plurality of discrete entity precursors in the imaging container. The liquid culture medium allows the plurality of discrete entities or plurality of discrete entity precursors to be suspended in the imaging container, thereby making it easier to handle the plurality of discrete entities or plurality of discrete entity precursors. In addition, the fluid or liquid culture medium can be biologically active to facilitate the culturing of biological samples. The liquid culture medium can include cell culture media (e.g., DMEM), buffers (e.g., PBS, PBDT), or synthetic hydrogels. The liquid culture medium can also include complex mixtures, such as naturally derived mixtures, such as Jellagel. TM , matrigel, and collagen.

[0020] In another preferred embodiment, the method includes the additional step of arranging a protective layer on top of the liquid culture medium. The protective layer can protect the liquid culture medium and the discrete entities from drying or being affected by the environment. The protective layer can be formed by any of the substances mentioned above in connection with the liquid culture medium. More than one protective layer can be formed. The protective layer and the liquid culture medium can be the same substance with different properties (such as density and viscosity). The difference between the protective layer and the liquid culture medium lies in the concentration, for example, 0.6% low melting point agarose will be very soft, while 2% low melting point agarose will be relatively hard. The elastic modulus of biological tissues varies greatly, for example, from bone matrix, cartilage, connective tissue to endometrium. One method of generating a variety of materials with good biocompatibility is to utilize bioinspired compositions containing certain key extracellular matrix components unique to these tissues. Such proteins can be, for example, thrombospondin, tenascin, COMP, collagen, collagen IV, in addition to hyaluronic acid and glycosylated groups. Gels with good biocompatibility can also be derived from bio-inks for 3D printing in the field of tissue engineering, thereby being used as liquid culture media or protective layers.

[0021] In another preferred embodiment, the method includes the additional step of adding reagents to the liquid medium to form a gel or polymer compound to encapsulate the plurality of discrete entities or the plurality of discrete entity precursors. By forming a gel or polymer compound, the plurality of discrete entities can be immobilized to prevent the movement of individual discrete entities, for example, when handling the imaging container. The matrix for encapsulating the plurality of discrete entities or the plurality of discrete entity precursors can be formed by functionalizing and / or crosslinking using various crosslinking agents or reactive groups on monomers added to the liquid medium.

[0022] In a further preferred embodiment, the method comprises the additional step of providing a compound, in particular a biological compound, sensitive to a property associated with the biological sample in the imaging container. The property associated with the biological sample can be determined based on the reaction of the compound. For example, the compound may include specialized reporter cells, FirePlex particles or reporter arrays, which are configured to capture target analytes (such as secreted proteins) so that they become detectable using appropriate detection and labeling reagents. Preferably, the compound is provided as a layer, in particular a monolayer, at the bottom of the imaging container. Therefore, the method may comprise the additional step of preparing the above layer at the bottom of the imaging container, in particular before arranging the plurality of discrete entities or a plurality of discrete entity precursors in the imaging container. Providing the compound as part of the discrete entity itself may result in uneven distribution of the compound in the discrete entity, thereby affecting the biological sample. In contrast, providing the compound in the form of a layer ensures that the compound is evenly distributed around the biological sample. In one example, the biological sample may be a clonal cell and the desired property associated with the biological sample may be the secretion of a specific monoclonal antibody (mAb). The compound is configured to react with the presence of a specific monoclonal antibody, for example by including a native antigen. In particular, the compound is configured to react to the presence of a specific monoclonal antibody in an optically detectable manner. For example, the presence of the specific monoclonal antibody may change the optical properties of the compound, such as transparency, color, or fluorescent signal, such as brightness, spectral change, fluorescence lifetime. The change in optical properties can be localized at the location of each target biological sample. Therefore, the presence of the specific monoclonal antibody can be detected by the first optical readout and / or the second optical readout. Once the presence of the specific monoclonal antibody is detected, the discrete entity in the biological sample secreting the monoclonal antibody can be marked as a target discrete entity. Then, the target discrete entity can be extracted or further processed.

[0023] In another preferred embodiment, each marker comprises at least one of luminescent microbeads, non-fluorescent microbeads, luminescent nanorulers and dyes. The microbeads and nanorulers may be fluorescent or phosphorescent. If the marker comprises fluorescent or non-fluorescent microbeads, different types of microbeads may be used, and these different types of microbeads may include microbeads of different sizes (diameters), different shapes, and different emission characteristics (fluorescence) (such as different emission spectra or different fluorescence lifetimes). The marker may be distributed on the surface of a discrete entity, embedded in a polymer compound, attached to a biological sample and / or embedded in a biological sample. In this embodiment, rapid, non-destructive and non-contact detection of the marker is possible. Preferably, the marker may be adjusted so that, for example, as further described in detail below, unique identification of at least one discrete entity among a plurality of discrete entities is achieved by luminescent microbeads randomly arranged in a three-dimensional manner but statically distributed in or at the discrete entity. The above elements of the marker can be easily read out at an extremely high acquisition speed, and are therefore very suitable for segmentation or feature extraction. In addition, by image processing, the elements of the marker can be easily removed from the image data. This is particularly advantageous as markers may otherwise obstruct observation of the contained biological specimen.

[0024] In another preferred embodiment, each marker comprises at least one element having an orientation component, in particular a nanoruler, a rod-shaped nanostructure or an elongated microbead. The orientation component may also be any other suitable object having a single central axis (such as a longitudinal axis) and the orientation of the object can be identified by the single central axis.

[0025] In another preferred embodiment, each marker comprises a three-dimensional pattern. In particular, the marker can be generated by etching, in particular photolithography, multiphoton lithography or two-photon etching. The three-dimensional pattern can be generated after forming a discrete entity. Using multiphoton etching, a three-dimensional pattern similar to a stacked barcode can be generated. Compared with a two-dimensional code, this three-dimensional pattern contains significantly more information content and allows a large number of unique codes to be generated. The three-dimensional pattern can also store additional information related to the source of the sample, the experiment and / or the user in the pattern, so that it is directly stored in the discrete entity. It is worth noting that this three-dimensional pattern is very stable over a long period of time, which not only has significant advantages in the processing flow described in this article, but is also very valuable in a biological sample library.

[0026] The present invention also relates to a device for testing a large number of biological samples, the device being configured to perform a method according to any of the preceding claims. The device comprises: an imaging container configured to receive a plurality of discrete entities and / or a plurality of discrete entity precursors, and an optical readout unit configured to perform at least one optical readout of the plurality of discrete entities. The control unit is configured to determine at least a first characterization of a marker for each of the plurality of discrete entities and at least one characteristic associated with the biological sample based on the at least one optical readout performed by the optical readout unit. In particular, the control unit is part of the device. Alternatively, the control unit may be arranged remotely from the device. The remotely arranged control unit may be connected to other parts of the device via a computer network.

[0027] The device has the same advantages as the protected method. In particular, the features in the dependent claims related to the method can also be used to supplement the device. In addition, the functions related to the device described herein can also be used to supplement the method.

[0028] The invention also relates to a computer program product comprising a program code which, when executed on a processor, enables the above-mentioned apparatus to perform one of the above-mentioned methods.

[0029] The computer program product has the same advantages as the method and the device described above. In particular, the features of the dependent claims directed to the method may supplement the computer program product.

[0030] The invention also relates to a computer-readable medium comprising the above-mentioned computer program. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Specific embodiments will be described below with reference to the accompanying drawings, wherein:

[0032] Figure 1 and 2 is a schematic diagram of a plurality of discrete entities arranged in an imaging container;

[0033] Figure 3 is a schematic diagram of steps of a method for testing a plurality of biological samples according to one embodiment;

[0034] Figure 4 is a schematic diagram of steps of a method for testing a plurality of biological samples according to another embodiment;

[0035] Figures 5 to 8 is a schematic diagram of steps of a method for testing a plurality of biological samples according to another embodiment;

[0036] Figures 9 to 12 is a schematic diagram of steps of a method for testing a plurality of biological samples according to another embodiment;

[0037] Figures 13 to 17 is a schematic diagram of steps of a method for testing a plurality of biological samples according to another embodiment;

[0038] Figures 18 to 19 is a schematic diagram of steps of a method for testing a plurality of biological samples according to another embodiment;

[0039] Fig. 20 is a schematic diagram of steps of a method for testing a plurality of biological samples according to another embodiment; and

[0040] Fig.21 Schematic diagram of the device for testing a large number of biological samples. DETAILED DESCRIPTION

[0041] Figure 1 and 2 is a schematic diagram of a plurality of discrete entities 100 arranged in an imaging container 102 .

[0042] Figure 1 and 2 , respectively, show cross-sectional schematic diagrams of an imaging container 102, which may be a culture dish, a microscope slide, a microplate, or a similar suitable vessel. Exemplarily, a plurality of discrete entities 100 are arranged in a single layer on a bottom surface 104 of the imaging container 102. To protect the discrete entities 100 and simplify the handling process, the imaging container 102 includes a liquid culture medium 106 in which the discrete entities 100 are suspended. The liquid culture medium 106 may be water, a cell growth medium, oil, or any other suitable liquid.

[0043] Exemplarily, the discrete entity 100 is formed as a microbead, including at least one polymeric compound, especially a polymeric compound that forms a hydrogel and / or is substantially optically transparent. Accordingly, this microbead is also referred to as a hydrogel microbead herein. The polymeric compound can be natural or synthetic, including agarose, alginic acid, chitosan, hyaluronic acid, dextran, collagen and fibrin, as well as poly(ethylene glycol), poly(hydroxyethyl methacrylate), poly(vinyl alcohol) and poly(caprolactone). In other examples, the polymeric compound includes a basement membrane extract, which may include laminin I, collagen I, collagen IV, vitronectin and fibronectin; and an extracellular matrix preparation, including, for example, Cultrex, Matrigel or Jellagel.

[0044] The discrete entity 100 may include one or several different polymeric compounds. In particular, the discrete entity 100 may include multiple parts, such as an inner core and an outer layer or shell surrounding the inner core. Each part may be made of a specific polymeric compound. In addition, the discrete entity 100 may also include parts made of other compounds that do not form hydrogels. Therefore, each part of the discrete entity 100 may have different properties. These properties include physicochemical properties, such as Young's modulus, refractive index, chemical composition, and functionalization.

[0045] Exemplarily, the shape of the discrete entity 100 is shown as a sphere. Alternatively, the discrete entity 100 has a different shape, such as an ellipsoid. The diameter of the discrete entity 100 can be in the range of 10 microns to 10 millimeters. Particularly preferred ranges are 10 microns to 100 microns, 50 microns to 250 microns, and 500 microns to 5 millimeters.

[0046] Each discrete entity 100 includes at least one biological sample 108 encapsulated in a hydrogel microbead formed of a polymer compound. Figure 1 and 2 108 is shown as a cell cluster. The cells can be eukaryotic cells or prokaryotic cells, including archaea, bacteria, plant cells, mammalian cells, non-mammalian cells and fungi. The cell cluster can be ellipsoidal, tumor-like or organ-like. In addition, the biological sample 108 can be a co-culture of different types of cells such as bacteria, viruses, prions, cell pathogens and / or multicellular parasites. The biological sample 108 can be used for analysis, diagnosis and / or treatment.

[0047] The discrete entity 100 shown in the figure also includes a marker 110. Exemplarily, Figure 1 and 2 The marker 110 shown is composed of a plurality of fluorescent microbeads. Preferably, during the formation of the discrete entity 100, the fluorescent microbeads are included and randomly dispersed in the polymeric compound. After the discrete entity 100 is formed, the microbeads are set in position in the discrete entity 100. This means that once the discrete entity 100 is formed, the position of the microbeads in the discrete entity 100 does not change. The discrete entity 100 may deform at a later point in time, for example, due to the effects of cell growth, culturing in a liquid, or processing the discrete entity 100. The diameter of the microbeads ranges from 50 nanometers to 500 nanometers.

[0048] The marker 110 may also be composed of structures or compounds other than fluorescent beads, such as non-fluorescent beads, regions of discrete entities 100 colored with dyes, or objects with a continuous distribution of phase or intensity. The marker 110 or a portion thereof may also be derived from the biological sample 108 .

[0049] In one example, the components of the marker 110 may include structures of the hydrogel microbeads generated during the formation of the discrete entity 100 (e.g., random defects on the surface of the hydrogel microbeads) and structures inherent to the method of forming the hydrogel microbeads. In this case, the components of the marker 110 may be located on the outside of the hydrogel microbeads, especially the surface. Other components of the marker 110 may be applied to the surface of the hydrogel microbeads, so that all or part of the marker 110 is located on the surface of the hydrogel microbeads. In addition, the marker 110 may also be applied to the surface of the inner phase of the multiphase hydrogel microbeads, so that the marker 110 will form a spherical layer inside the hydrogel microbeads of the discrete entity 100. In addition, the components of the marker 110 can be a color gradient or an intensity gradient.

[0050] In another example, the marker 110 includes a nanoruler, where the nanoruler is at least two intensity or phase point objects physically connected in a rigid manner. For example, the nanoruler can be composed of a nucleic acid and a series of dyes with different spectral and / or lifetime properties. The dye is coupled to the nucleic acid at a predetermined distance. Nanorulers and similar structures are components of the marker 110 and can be used to generate markers 110 as an alternative or supplement to microbeads and the like. Since the nanoruler has an inherent orientation or shape, it can be directly represented as a vector or a respective shape when generating a representation of the marker 110. Since each vector can point in any direction, the dynamic range and the number of unique markers 110 are greatly increased. Even if the number of nanorulers in a hydrogel microbead of the discrete entity 100 is the same, and the placement of each nanoruler relative to the X, Y, Z position of the center of mass of the hydrogel microbead is the same, the rotational freedom will result in a large number of possible orientations thereof, resulting in a large number of unique representations of the marker 110. Similar effects can also be achieved by using microbeads or similar fluorescent particles with asymmetric or elongated shapes.

[0051] In another example, the components of the marker 110 can be generated after forming the hydrogel microbeads of the discrete entity 100. This can be achieved by adding compounds to the hydrogel microbeads when forming the discrete entity 100, wherein these compounds form the components of the marker 110. After forming the discrete entity 100, the compounds contained in the hydrogel microbeads can be photochemically activated, deactivated or bleached. In a subsequent etching, especially photolithography step, the compounds can be photochemically activated, deactivated or bleached by focusing a beam or imaging or projecting a pattern on the discrete entity 100.

[0052] In further examples, the components of the marker 110 may be generated in a random or deterministic photochemical or photophysical manner. If the components are randomly generated, the variation regions are generated at random locations in the hydrogel microbeads of the discrete entity 100. For example, a random distribution such as stripes, dots, or similar characteristic distributions may be randomly generated. The photolithographically generated marker 110 may be in the form of a barcode or a stacked barcode. A multiphoton lithography apparatus 2100 may be used to generate the photochemical or photophysical variation regions arranged in a three-dimensional pattern in the hydrogel microbeads of the discrete entity 100.

[0053] If the components are generated deterministically, the generation of the varying regions can be such that, for each hydrogel microbead of the discrete entity 100, a unique pattern of varying regions is generated. In particular, the pattern can take the form of a barcode. In addition, this unique pattern can also encode other information, such as a unique identifier and further information including the source of the sample or biopsy embedded in the discrete entity 100, the processing of the sample, the date, time, experimenter. Importantly, this type of three-dimensional code can be written using multiphoton etching, thereby greatly increasing the bit depth of the code, thereby increasing the amount of information encoded using the unique pattern.

[0054] The pattern of the photochemical or photophysical change area of ​​the discrete entity 100 generated by photolithography can be a positive or a negative. For example, a negative can be generated by photochemically uncaging or deprotecting the protected binding site, thereby generating a deprotected binding site in the corresponding area. Then, the dye can be covalently coupled to the unprotected reaction site using click chemistry, thereby converting the negative into a positive, for example, by soaking the hydrogel microbeads in a reactive dye solution and then washing away the unbound dye molecules. Since the protected binding site can be covalently linked to the hydrogel polymer, the covalently coupled dye molecules or other covalently coupled components of the marker 110 form a substantially fixed pattern or distribution. By generating a unique pattern or generating a unique distribution of these specific locations, the marker 110 is directly generated (directly generating a positive) or indirectly generated (directly generating a negative and then developing into a positive). In any case, the components of the marker 110 are optically detectable, such as detecting a phase or intensity object through a microscope. Therefore, the marker 110 is optically detectable. The hydrogel beads of discrete entities 100 must be transparent, at least to the extent that the biological specimen 108 and marker 110 are optically detectable.

[0055] The discrete entity 100 may be prepared outside the imaging container 102 and then transferred into the imaging container 102. The discrete entity 100 may be formed by methods such as electrospraying, emulsification, etching, and 3D printing. The formation of the discrete entity 100 may be performed in a dedicated culture vessel such as a spinner bottle or a microplate. In particular, the discrete entity 100 is formed by a microfluidic device, which may be part of the device 2100 for testing a large number of biological samples 108. Alternatively, a plurality of discrete entity precursors are arranged in the imaging container 102, and the plurality of discrete entities 100 are formed inside the imaging container 102.

[0056] Figure 1 The diagram of FIG. 1 depicts a step of a method for testing a plurality of biological samples 108. The biological samples 108 encapsulated in discrete entities 100 form a plurality of biological samples 108 to be tested. Each biological sample 108 can be uniquely identified by a marker 110 that belongs to the same discrete entity 100 as the biological sample 108. Figure 1 , a plurality of discrete entities 100 are labeled using identifiers BC00001 to BC00010.

[0057] Figure 1 The steps depicted in the embodiment include generating a first optical readout of the plurality of discrete entities 100, for example, by imaging the plurality of discrete entities 100 or portions thereof using a microscope. In particular, the optical readouts may be images of the plurality of discrete entities 100 or portions thereof, respectively. After further processing, a first representation of all markers 110 of the discrete entities 100 contained in the first readout is generated based on first data generated by the first optical readout. Furthermore, based on the first data corresponding to the first optical readout, at least one characteristic associated with the plurality of biological samples 108 is determined. For example, such a characteristic may be the presence of a certain biomarker 110. Figure 2 Another step of the method is described.

[0058] Figure 2 ' depicts another step in the method of testing a plurality of biological samples 108. Figure 2 The steps depicted in the embodiment include: after the discrete entities 100 (particularly the biological samples 108 as part of the discrete entities 100) are cultured, generating a second optical readout of the plurality of discrete entities 100. For example, the culture may include treating the biological samples 108 with a compound or otherwise stimulating the biological samples 108. Similar to the first optical readout, a second optical readout is performed, and second data is generated based on the second optical readout. The second data is further processed to determine a second representation of all markers 110 of the discrete entities 100 contained in the second readout, and at least one characteristic associated with the plurality of biological samples 108.

[0059] from Figure 2As can be seen from the markings in Figure 1 The steps depicted and Figure 2 Between the depicted steps, individual discrete entities 100 have been rearranged. This rearrangement may be caused by moving the imaging container 102 or other deformations. Because each discrete entity 100 is uniquely labeled with a marker 110, individual discrete entities 100 can be tracked between steps. In this way, a user can track the response of a single biological specimen 108 to the culture by comparing the characteristics determined from the second optical readout with the characteristics determined from the first optical readout.

[0060] Figure 1 and Figure 2 The invention is used to illustrate the use of a discrete entity 100 that combines a biological sample 108 with a unique marker 110 in a hydrogel microbead in a method for testing a plurality of biological samples 108. The above characteristics, in particular the characteristics of the discrete entity 100, can be realized in all embodiments of the method. Below, the method will be described in more detail with reference to different embodiments. In this document, when referring to the discrete entity 100 used in the method, the terms "a plurality of discrete entities 100" and "discrete entity 100" can be used interchangeably.

[0061] Figure 3 FIG. 1 is a schematic diagram of steps of a method 108 for testing a plurality of biological samples according to one embodiment.

[0062] The discrete entity 100 may be formed outside the imaging container 102, or may be formed inside the imaging container 102 by encapsulating one of the plurality of biological samples 108 in a hydrogel bead. In addition, a marker 110 is generated in a corresponding discrete entity 100. The marker 110 may be encapsulated in the same step as the biological sample 108, and / or the marker 110 may be generated after the hydrogel bead used to encapsulate the biological sample 108 is formed. As with encapsulating the biological sample 108, the generation of the marker may be performed outside or inside the imaging container 102. If the generation of the marker is performed inside the imaging container 102, the hydrogel bead containing only the biological sample 108 is also referred to as a discrete entity precursor.

[0063] After forming and / or arranging the plurality of discrete entities 100 inside the imaging container 102, a first optical readout is performed in step S300. First data generated according to the first optical readout is analyzed. For each discrete entity 100 captured by the first optical readout, a first representation of the marker 110 of the discrete entity 100 is generated. Through the first representation, the corresponding discrete entity 100 can be tracked in future readouts. Similarly, at least one characteristic associated with the biological sample 108 is determined based on the first data. The first representation and the specific value of the characteristic can be stored for each discrete entity 100 captured by the first optical readout. In addition, the first data corresponding to the first optical readout can also be stored.

[0064] In step S302, the plurality of discrete entities 100 are cultured in the imaging container 102. The culture step may include: performing various treatments, using reagents, such as using compounds, biological agents, DNA, RNA, proteins, antibodies, antibody fragments, aptamers, or physical stimulation, such as mechanical, electrical, photophysical stimulation, scratching, scraping, ablation, photoablation, temperature changes, physiological conditions changes (pH, O2, CO2, N2 concentration). The culture step may also include adding cell types, bacteria, archaea, fungi, multicellular eukaryotes, parasites, animals and plants. In particular, the culture step includes leaving the biological sample 108 for a predetermined time.

[0065] After the incubation step, step S300 is repeated for the second optical readout. Based on the second data generated by the second optical readout, a second representation of each marker 110 for each discrete entity 100 captured by the second optical readout is generated. Then, the captured discrete entity 100 can be identified based on the second representation. At least one characteristic associated with the biological sample 108 is also determined based on the second data. By identifying based on the first representation and the second representation, the value of at least one characteristic of each biological sample 108 is compared between the acquisition of the first optical readout and the second optical readout. The second representation and the specific value of the characteristic can be stored for each discrete entity 100 captured by the second optical readout. The same method can also be used for other optical readouts. In addition, the first data corresponding to the first optical readout can also be stored.

[0066] Steps S300 and S302 may be repeated again for further optical readout, thereby generating a continuous test number and / or time series. In this way, multiple discrete entities 100 may be identified as target discrete entities. In step S304, at least one of the discrete entities 100 that has been identified as a target discrete entity is removed from the imaging container 102 for further processing. Further processing may include: extracting a biological sample 108 from the discrete entity 100, further culturing and amplification, biologic production, bioprocessing, fermentation, gene cloning, and downstream analysis. Downstream analysis may include genomic, transcriptomic, proteomic analysis, transcription factor binding analysis (e.g., ChIP-Seq), DNA methylation analysis, metabolomic analysis, and the like.

[0067] Figure 4 is a schematic diagram of steps of a method for testing a plurality of biological samples 108 according to another embodiment.

[0068] Figure 4 The method embodiment shown is Figure 3 The embodiment shown differs in that the culturing step is performed outside the imaging container 102. Before the step S400 of performing the optical readout, the liquid culture medium 106 in which the discrete entities 100 are suspended is removed from the imaging container 102 and transferred to a separate vessel 400, exemplarily shown as a stirring bottle. In step S402, the plurality of discrete entities 100 are cultured, stained, and / or washed in the separate vessel 400 and then transferred back to the imaging container 102 for another optical readout. After repeating steps S400 and S402 at least once, in step S404, at least one of the discrete entities 100 that has been identified as a target discrete entity is removed from the imaging container 102 for further processing.

[0069] Figures 5 to 8 is a schematic diagram of steps of a method for testing a plurality of biological samples 108 according to another embodiment.

[0070] In this embodiment, the encapsulated biological sample 108 is a cloned cell for testing the production of a monoclonal antibody (mAb). In addition to the biological sample 108, a target is also encapsulated into the discrete entity 100. The target can be a target cell or a target molecule, and in this embodiment forms a compound that is sensitive to the relevant characteristics of the biological sample 108. According to this embodiment, the purpose of this method is to find and extract the cloned cell that produces the monoclonal antibody that best binds to the target.

[0071] Figure 51 shows a first step of the method, in which a plurality of discrete entities 100 are arranged in a liquid culture medium 106 within an imaging container 102. A protective layer 500 is formed on top of a monolayer formed by the liquid culture medium 106 and the discrete entities 100. The protective layer 500 may be formed of the same material as the liquid culture medium 106 (e.g., having a different density, viscosity, and / or concentration). The protective layer 500 prevents the liquid culture medium 106 from drying out and prevents the liquid culture medium 106 from spilling when the imaging container 102 is handled.

[0072] Figure 6 The view of shows the second step of the method, in which an optical readout of at least part of a plurality of discrete entities 100 is generated. Data is generated based on the optical readout. For example, the data is further processed by a computer to generate a characterization of the markers 110 of the discrete entities 100 captured by the optical readout. In addition, four quantities are determined as characteristics related to the biological sample 108, i.e., the clonal cells. As a first characteristic, the degree of binding of the monoclonal antibodies produced by each clonal cell to the target is determined. As a second characteristic, the functionality of the monoclonal antibodies is determined. As a third characteristic, the solubility of the monoclonal antibodies is determined. Finally, as a fourth characteristic, the monoclonal antibody yield of each clonal cell is determined. For this purpose, the monoclonal antibodies are labeled with a fluorescently labeled secondary antibody that reacts with the isotype of the monoclonal antibodies. Then, the fluorescence intensity can be used to read how many monoclonal antibodies are found in the discrete entity, in its vicinity, on the target cell expressing the antigen, and / or on the structure such as the microbeads or nanostructures carrying the antigen. The above characteristics can be inferred from the relationship between the number of monoclonal antibodies found in these blocks. Similarly, the presence of aggregates can be detected as fluorescent aggregates, allowing the solubility of the antibody to be inferred. More importantly, if reporter cells expressing the antigen are used, two very important aspects can be tested: first, the extent to which the monoclonal antibody affects the biological function of the target cell. For example, it may be found that two different monoclonal antibodies bind to the same receptor tyrosine kinase with apparently similar affinities, but only one of them inhibits signaling. This can be easily detected by using appropriately genetically modified reporter cells that report the corresponding downstream signaling by expressing a fluorescent protein such as mCherry, GFP, or by changes in the FRET signal. Second, binding to the native epitope can be tested. Depending on the type of microscopic readout and labeling used, these tests can provide qualitative or quantitative information. If individual binding events between the antibody and the target are monitored over a long period of time, the actual binding strength, KD value, and ON / OFF rate (on / off rate) can be determined. The same effect can be achieved if fluorescence correlation spectroscopy is used in addition to the imaging readout. This more complex and time-consuming measurement can be used as a secondary test to allow in-depth testing of a small number of target clones.

[0073] According to these four characteristics, the most ideal clone cell is determined. The discrete entity 100 including the most ideal clone cell is marked as the target discrete entity and is Figure 7 1. The extracted discrete entities 100 are extracted in the third step shown in the view of FIG. 1. Exemplarily, extracting one of the discrete entities 100 includes: cloning cells to produce a large number of monoclonal antibodies that strongly bind to the target and exhibit good solubility and functionality. In further processing, the extracted discrete entities 100 can be identified based on the characterization of the markers 110 that have been stored together with the determined characteristics of each discrete entity 100.

[0074] Figure 8 The view of shows another method for extracting the desired clonal cells. In this alternative, a hydrolyzing agent 800 is introduced into the liquid culture medium 106 to dissolve the hydrogel microbeads of the discrete entity 100. After the hydrogel microbeads are hydrolyzed, the biological sample 108, i.e., the clonal cells in this example, can be extracted directly from the liquid culture medium 106 (e.g., by suction). The hydrolyzing agent 800 can be a protease, such as collagenase or a neutral protease. In addition, as an alternative to the hydrolyzing agent 800, specific cleavage sites and chemical components can be added to the hydrogel or polymer compound used to generate the discrete entity. For example, such cleavage groups and chemical components can be cleavage groups that are sensitive to certain chemicals, ultraviolet rays, temperature, or specific enzymes, which can then be used to easily dissolve the discrete entity. Such cleavage groups and chemical components may or may not be bidirectional.

[0075] Figures 9 to 12 is a schematic diagram of steps of a method for testing a plurality of biological samples 108 according to another embodiment.

[0076] As in the previous embodiment, in this embodiment, the coated biological sample 108 is also a clonal cell for testing the production of a monoclonal antibody. However, in this embodiment, the target is provided as a layer 900 (e.g., a cell monolayer composed of native antigens of the desired monoclonal antibody) at the bottom of the imaging container 102. The arrangement of the plurality of discrete entities 100 composed of clonal cells and a cell monolayer containing native antigens is as shown in FIG. Fig. 9 , corresponding to the first step of the method.

[0077] Fig. 9 9 shows a first step of the method, in which a layer 900 consisting of a target and a plurality of discrete entities 100 is arranged in a liquid medium 106 within an imaging container 102. As in the above embodiment, in this embodiment, the target is a compound sensitive to a relevant property of a biological sample 108 encapsulated in the discrete entities 100. In this embodiment, a protective layer 500 is also formed over the liquid medium 106 and the monolayer formed by the discrete entities 100 and the target.

[0078] Fig.10 The second step of the method is shown in FIG. 1 . The second step is performed after a predetermined time has passed and the monoclonal antibodies produced by the cloned cells have time to diffuse out of the hydrogel microbeads of the discrete entity 100. Some of the monoclonal antibodies will bind to the native antigens of the target in the layer 900 located at the bottom of the imaging container 102. Figures 10 to 12 In the second step, an optical readout of at least a portion of the plurality of discrete entities 100 and / or at least a portion of the layer 900 is generated. Based on data corresponding to the optical readout, a representation of the marker 110 is generated and can be analyzed and / or stored.

[0079] In addition, the degree of binding of the monoclonal antibody produced by each clone cell to the target, as well as the functionality and solubility of the monoclonal antibody and the yield of each clone cell are determined. Based on these characteristics, the most ideal clone cell is determined. The discrete entity 100 including the most ideal clone cell is marked as the target discrete entity and is Fig.11 In further processing, the extracted discrete entities 100 may be identified based on the representations of the landmarks 110 that have been stored together with the determined characteristics of each discrete entity 100 .

[0080] Fig.12 , shows an alternative method for extracting desired clonal cells, in which a hydrolyzing agent 800 is introduced into a liquid culture medium 106 in which the hydrogel beads of discrete entities 100 are dissolved. After hydrolysis of the hydrogel beads, the biological sample 108, i.e., the clonal cells in this example, can be directly extracted from the liquid culture medium 106.

[0081] Figures 13 to 17 is a schematic diagram of steps of a method for testing a plurality of biological samples 108 according to another embodiment.

[0082] Fig.13 The view of FIG. 1 shows the first step of the method, in which a plurality of discrete entities 100 are arranged in a liquid culture medium 106 in an imaging container 102. A polymerizing agent is added to the liquid culture medium 106 to form a polymer compound 1300 that encapsulates the plurality of discrete entities 100, the polymer compound having pores 1302 with relatively large pore sizes so that the stimulation reagent can diffuse quickly. Alternatively, a gel can also be formed in the liquid culture medium 106 by adding a gelling agent. A protective layer 500 can be formed on the polymer compound and the monolayer formed by the discrete entities 100.

[0083] Fig.14 The view of shows the second step of the method, in which a stimulation agent is added to the polymeric compound 1300. Fig.14In the method, the stimulant is represented by a polymer compound 1300 formed by a liquid medium 106 in different filling modes. The stimulant is an experimental stimulus that causes the biological sample 108 encapsulated in the discrete entity 100 to react in a certain observable manner. The purpose of the method is to observe the reaction of the biological sample 108 with the stimulant and select the biological sample 108 that reacts in a desired manner.

[0084] After the stimulation reagent is added, the stimulation reagent can diffuse into the hydrogel microbeads of the discrete entity 100 through the polymer compound 1300, thereby reacting with the biological sample 108. Fig.15 view, especially through Figures 14 to 15 The filling of the polymeric compound 1300 matches the different filling of the discrete entities 100, showing the diffusion of the stimulation agent into the hydrogel microbeads of the discrete entities 100.

[0085] Fig.16 1 shows the third step of the method, in which additional polymerizing agent is added to the polymerizing compound 1300 to form a new polymerizing compound 1304 having smaller pores 1306, which can prevent the stimulation agent from diffusing out of the hydrogel microbeads. Before or after adding the polymerizing agent, the remaining stimulation agent can be washed out of the polymerizing compound 1300, 1304.

[0086] Fig.17 , illustrates a fourth step of the method, in which an optical readout of at least a portion of the plurality of discrete entities 100 is generated. Data generated based on the optical readout is further processed to generate a representation of the markers 110 of the discrete entities 100 captured by the optical readout. In addition, at least one characteristic associated with the biological sample 108 is determined based on the data. In this embodiment, the characteristic is a reaction of the biological sample 108 with a stimulus reagent, such as Fig.17 The production of the antibody 1700 is shown. Then, based on the characteristics, the target discrete entity is determined which can be extracted in the next step of the method.

[0087] Fig.18 and 19 is a schematic diagram of steps of a method for testing a plurality of biological samples 108 according to another embodiment.

[0088] In this embodiment, the biological sample 108 is encapsulated in the hydrogel microbeads together with the compound 1802, in particular the biological compound 1802, wherein the compound 1802 is sensitive to the relevant characteristics of the biological sample 108 in the imaging container 102, for example, a molecule used in the FirePlex, NanoArrays or OrigamiSeq testing technology, such as Fig.18The pore size of the hydrogel microbeads is selected so that the target can diffuse out of the hydrogel microbeads after the compound 1802 reacts.

[0089] from Fig.19 As can be seen from the view of FIG. 1 , the sensitive compound 1802 has reacted and diffused out of the hydrogel microbeads of the discrete entities 1800. The compound 1802 forms a bottom phase 1900 at the bottom of the imaging container 102. The optical readout also captures the bottom phase 1900. Based on the optical readout, at least one characteristic associated with the biological sample 108 is determined in the bottom phase 1900. Fig.19 In the view of FIG. 1 , multiple molecules of compound 1802 have reacted according to the characteristics, and discrete entities 1800 located directly above the reacted compound 1802 have been marked as target discrete entities. Then, in the next step, these discrete entities 1800 can be extracted for further processing.

[0090] Fig. 20 A schematic diagram showing steps of a method for testing a plurality of biological samples 108 according to further embodiments is shown.

[0091] In this embodiment, the discrete entities 1800 are suspended in the oil phase 2000. In other words, in this embodiment, the liquid medium 106 is oil. The advantage of oil is that it can effectively seal the discrete entities and prevent water-soluble compounds and proteins from escaping from the discrete entities 100. In some applications, this may be necessary, and the use of an additional sealing layer for sealing may not be feasible, too time-consuming or too expensive.

[0092] Fig.21 A schematic diagram of an apparatus 2100 for testing a plurality of biological samples 108 is shown.

[0093] The device 2100 is configured to perform the method of testing a large number of biological samples 108 described herein. The system includes an imaging container 102, an optical readout unit 2102, and a control unit 2104, which is exemplarily formed as a computer system. The optical readout unit 2102 is exemplarily formed as a microscope for capturing images of the imaging container 102 and the discrete entities 100 contained therein. The optical readout unit 2102 is further connected to the computer system. The computer system is configured to perform at least a portion of the method described herein. The computer system can be configured to execute a machine learning algorithm. The computer system and the microscope can be independent entities from each other, but can also be integrated in the same housing. The computer system can be part of a central processing system of the microscope, and / or the computer system can be part of a subcomponent of the microscope, such as a sensor, actuator, camera or lighting device of the microscope.

[0094] The computer system may be a local computer device (e.g., a personal computer, laptop, tablet computer, or mobile phone) having one or more processors and one or more storage devices, or a distributed computer system (e.g., a cloud computing system having one or more processors and one or more storage devices distributed in different locations, such as a local client and / or one or more remote server clusters and / or data centers). The computer system may include any circuit or combination of circuits. In one embodiment, the computer system may include one or more processors, and the processor may be of any type. As used herein, the processor may refer to any type of computing circuit, such as, but not limited to, a microprocessor, microcontroller, complex instruction set computing (CISC) microprocessor, reduced instruction set computing (RISC) microprocessor, very long instruction word (VLIW) microprocessor, graphics processor, digital signal processor (DSP), multi-core processor, field programmable gate array (FPGA), or any other type of processor or processing circuit. Other types of circuits that may be included in the computer system may be custom circuits, application-specific integrated circuits (ASICs), or similar circuits, such as one or more circuits (such as communication circuits) for wireless devices such as mobile phones, tablet computers, laptops, two-way radios, and similar electronic systems. The computer system may include one or more storage devices, which may include one or more storage elements suitable for a particular application, such as main memory in the form of random access memory (RAM), one or more hard disk drives and / or one or more drives that can operate removable media such as compact disks (CDs), flash memory cards, digital video disks (DVDs), etc. The computer system X20 may also include a display device, one or more speakers, and a keyboard and / or controller, which may include a mouse, trackball, touch screen, voice recognition device, or any other device that allows a system user to input information to and receive information from the computer system.

[0095] Some or all of the method steps may be performed by (or using) a hardware device, such as a processor, a microprocessor, a programmable computer or an electronic circuit. In some embodiments, some of the most important method steps may be performed by such a device.

[0096] According to certain implementation requirements, embodiments of the present invention may be implemented by hardware or software. The above implementation may be performed using non-temporary storage media, such as digital storage media such as floppy disks, DVDs, Blu-ray discs, CDs, ROMs, PROMs, EPROMs, EEPROMs, or flash memories, on which electronically readable control signals may be stored and which cooperate (or are capable of cooperating) with the programmable computer system to perform the corresponding method. Therefore, the digital storage medium may be computer readable.

[0097] Some embodiments according to the invention further comprise a data carrier having electronically readable control signals, capable of cooperating with the programmable computer system, such that one of the methods described herein is performed.

[0098] Generally speaking, the embodiments of the present invention can be implemented as a computer program product with a program code, which can be used to perform one of the methods described when the computer program product runs on a computer. For example, the program code can be stored on a machine-readable carrier.

[0099] Other embodiments comprise the computer program for performing one of the methods described herein, stored on a machine readable carrier.

[0100] In other words, an embodiment of the present invention is a computer program having a program code for performing one of the methods described herein, when the computer program runs on a computer.

[0101] Therefore, another embodiment of the present invention provides a storage medium (or data carrier, or computer-readable medium), which includes a computer program stored thereon for performing one of the methods described herein when executed by a processor. The data carrier, digital storage medium or recording medium is generally tangible and / or non-transitory. Another embodiment of the present invention is an apparatus as described herein, comprising a processor and a storage medium.

[0102] Therefore, a further embodiment of the invention is a data stream or a sequence of signals representing the computer program for performing one of the methods described herein.For example, the data stream or the sequence of signals may be configured to be transmitted via a data communication connection, for example via the Internet.

[0103] A further embodiment comprises a processing means, for example a computer or a programmable logic device 2100 , configured to or adapted to perform one of the methods described herein.

[0104] A further embodiment comprises a computer having installed thereon the computer program for performing one of the methods described herein.

[0105] Further embodiments according to the invention include an apparatus or system configured to transfer (e.g., electronically or optically) a computer program for performing one of the methods described herein to a receiver. For example, the receiver may be a computer, a mobile device 2100, a storage device 2100, or a similar device. For example, the apparatus or system may include a file server for transferring the computer program to the receiver.

[0106] In some embodiments, a programmable logic device 2100 (e.g., a field programmable gate array) may be used to perform some or all of the functions of the methods described herein. In some embodiments, the field programmable gate array may cooperate with a microprocessor to perform one of the methods described herein. In general, the methods are preferably performed by any hardware device.

[0107] As used herein, the term "and / or" includes any and all combinations of one or more of the associated listed items and may be abbreviated as " / ".

[0108] Although certain aspects have been described in the context of an apparatus, it is apparent that these aspects also represent a description of a corresponding method, wherein a block or means 2100 corresponds to a method step or a feature of a method step. Likewise, various aspects described in a method step also represent a description of a corresponding block or item or feature of a corresponding apparatus.

[0109] Reference numerals list

[0110] 100 discrete entities

[0111] 102 Imaging Container

[0112] 104 Bottom

[0113] 106 Liquid culture medium

[0114] 108 Biological samples

[0115] 110 Markers

[0116] 400 Utensils

[0117] 500 protection layers

[0118] 800 Hydrolyzing Agent

[0119] 900th floor

[0120] 1300 Polymeric compounds

[0121] 1302 Porosity

[0122] 1304 Polymeric compounds

[0123] 1306 Porosity

[0124] 1700 Antibodies

[0125] 1800 Discrete entities

[0126] 1802 Compound

[0127] 1900 bottom phase

[0128] 2000 oil phase

[0129] 2100 Device

[0130] 2102 Optical Readout Unit

[0131] 2104 Control Unit

Claims

1. A method for testing a plurality of biological samples (108), comprising the following steps: a) preparing a plurality of discrete entities (100), wherein each discrete entity (100) comprises a polymer compound, at least one biological sample (108) and a marker (110); b) arranging the plurality of discrete entities (100, 1800) in an imaging container (102); c) generating at least one first optical readout of at least one discrete entity (100, 1800) of the plurality of discrete entities (100, 1800); d) determining, based on the first optical readout, a first representation of a marker (110) of at least one discrete entity (100, 1800) of the plurality of discrete entities (100, 1800) and at least one property associated with the biological sample (108); and e) identifying at least one discrete entity (100, 1800) from the plurality of discrete entities (100, 1800) from the imaging container (102) as a target discrete entity (100, 1800) based on the at least one characteristic associated with the biological sample (108) and the first representation of the marker (110) of the at least one discrete entity (100, 1800).

2. A method for testing a plurality of biological samples (108), comprising the following steps: a) preparing a plurality of discrete entity precursors, wherein each of the precursors comprises a polymer compound and at least one biological sample (108) coated by the polymer compound; b) arranging the plurality of discrete solid precursors in an imaging container (102); c) creating a plurality of discrete entities (100, 1800) from the plurality of discrete entity precursors, wherein each of the discrete entities (100, 1800) comprises the polymeric compound, the biological sample (108) and a marker (110); e) generating at least one first optical readout of at least one discrete entity (100, 1800) of the plurality of discrete entities (100, 1800); f) determining, based on the first optical readout, a first representation of a marker (110) of at least one discrete entity (100, 1800) of the plurality of discrete entities (100, 1800) and at least one property associated with the biological sample (108); and g) identifying at least one discrete entity (100, 1800) from the plurality of discrete entities (100, 1800) from the imaging container (102) as a target discrete entity (100, 1800) based on the at least one characteristic associated with the biological sample (108) and the first representation of the marker (110) of the at least one discrete entity (100, 1800).

3. The method according to claim 1 or 2, wherein: The biological sample (108) and the marker (110) are coated by the polymer compound; and / or, wherein the polymer compound includes the marker (110), and the biological sample (108) is coated by the polymer compound regardless of whether it is marked by the marker (110) or not.

4. The method according to any of the preceding claims, comprising the additional step of fixing the plurality of discrete entities (100, 1800) or the plurality of discrete entity precursors in the imaging container (102).

5. The method according to any of the preceding claims, comprising the additional step of extracting at least one discrete entity (100, 1800) of the plurality of discrete entities (100, 1800) from the imaging container (102) based on the at least one characteristic associated with the biological sample (108) and the first representation of the marker (110) of the at least one discrete entity (100, 1800).

6. The method according to any one of the preceding claims, comprising the additional step of: generating at least one second optical readout after a preset period of time; determining a second representation of the marker (110) of at least one discrete entity (100, 1800) of the plurality of discrete entities (100, 1800) and a property associated with the biological sample (108) based on the second optical readout; comparing the first representation and the second representation to identify at least one discrete entity (100, 1800) of the plurality of discrete entities (100, 1800); comparing the characteristic associated with the biological sample (108) determined based on the first optical readout with the characteristic associated with the biological sample (108) determined based on the second optical readout; as well as Preferably, at least one discrete entity (100, 1800) among the plurality of discrete entities (100, 1800) is extracted from the imaging container (102) according to the above comparison.

7. The method according to claim 6, comprising the additional step of culturing the discrete entity (100, 1800), in particular culturing the biological sample (108) as part of the discrete entity (100, 1800), between the first optical readout and the second optical readout.

8. The method according to any of the preceding claims, comprising the additional step of arranging a fluid or liquid culture medium (106, 2000) in the imaging container (102) before arranging the plurality of discrete entities (100, 1800) or the plurality of discrete entity precursors in the imaging container (102).

9. The method according to claim 8, comprising the additional step of arranging a protective layer (500) on the liquid culture medium (106, 2000).

10. The method according to claim 8 or 9, comprising the additional step of adding a reagent to the liquid culture medium (106, 2000) to form a gel or polymer compound (1300, 1304) to coat the plurality of discrete entities (100, 1800) or the plurality of discrete entity precursors.

11. The method according to any of the preceding claims, comprising the additional step of providing a compound (1802), in particular a biological compound, which is sensitive to the property related to the biological sample (108) in the imaging container (102), wherein the property related to the biological sample (108) is determined based on the reaction of the compound.

12. The method according to claim 11, wherein: The compound is provided as a layer (900) at the bottom of the imaging container (102).

13. A method according to any one of the preceding claims, wherein: Each marker (110) includes at least one of luminescent microbeads, non-fluorescent microbeads, nanorulers and dyes.

14. A method according to any one of the preceding claims, wherein: Each marker (110) comprises at least one element having an oriented component, in particular a nanoruler, a rod-shaped nanostructure or an elongated microbead.

15. A method according to any one of the preceding claims, wherein: Each marker (110) comprises a three-dimensional pattern.

16. A device (2100) for testing a plurality of biological samples (108), configured to perform the method according to any one of the preceding claims, the device (2100) comprising: An imaging container (102) configured to receive a plurality of discrete entities (100, 1800) and / or a plurality of discrete entity precursors; as well as an optical readout unit (2102) configured to perform at least one optical readout of the plurality of discrete entities (100, 1800); Wherein, the control unit (2104) is configured to determine at least a first characterization of the marker (110) of each discrete entity (100, 1800) of the plurality of discrete entities (100, 1800) and at least one characteristic associated with the biological sample (108) based on the at least one optical readout performed by the optical readout unit (2102).

17. A computer program product comprising a program code, which, when executed on a processor, enables the apparatus (2100) according to claim 16 to perform the method according to any one of claims 1 to 15.

18. A computer readable medium comprising the computer program product of claim 17.